Researchers at the University of Colorado Anschutz Medical Campus have discovered that inhibiting the Mdm2 protein with a drug called nutlin prevents the synaptic destruction associated with Alzheimer’s disease, offering a promising new avenue for therapy. This approach, which diverges from traditional strategies focusing on amyloid plaque removal, could potentially halt the disease’s progression and is set to undergo further testing in animal models.
Researchers at CU Anschutz have discovered a new potential method to target the disease.
Scientists at the University of Colorado Anschutz Medical Campus have discovered that inhibiting a crucial protein can halt the damage to synapses and dendritic spines often observed in DOI: 10.1523/ENEURO.0175-23.2024